A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients

Overview

Journal Indian J Crit Care Med

Specialty Critical Care

Date 2021 Dec 29

PMID 34963727

Citations 5

Authors

Kapil G Zirpe

Yatin Mehta

Rahul Pandit

Rajesh Pande

Abhijit M Deshmukh

Saiprasad Patil

Sagar Bhagat

Hanmant Barkate

Affiliations

Soon will be listed here.

Abstract

Background: This study presents a real-world scenario for prescription pattern, efficacy, and safety data on the current clinical use of intravenous fosfomycin in critically ill patients in Indian settings.

Patients And Methods: This was a retrospective cohort study conducted for a period of 10 months among critically ill patients admitted to hospital's critical care unit. The primary objective of the study was to analyze the prescription pattern of intravenous fosfomycin, and the secondary objective was to evaluate the safety profile and patient outcomes.

Results: A total of 309 patients were enrolled, and they were diagnosed with bacteremia (45.3%), pneumonia (15.85%), septic shock (14.24%), and urinary tract infections (UTI) (13.91%). The average dose of fosfomycin given was 11.7 ± 4.06 gm/day. The average duration of the therapy was 4.85 ± 3.59 days with a median duration of 4 days. Fosfomycin was given at 8 hourly dosing frequency to maximum (45.6%) cases. Hypokalemia was the most observed adverse event. The overall survival was seen in 55% of patients.

Conclusion: Our data suggest that UTI, infection caused by and a daily dose of >12 g were associated with better clinical outcomes. The overall survival of critically ill patients receiving fosfomycin was 55%.

How To Cite This Article: Zirpe KG, Mehta Y, Pandit R, Pande R, Deshmukh AM, Patil S, . A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients. Indian J Crit Care Med 2021;25(9):1055-1058.

Citing Articles

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae.

Onal U, Tuzemen N, Kucukdemirci Kaya P, Iscimen R, Kelebek Girgin N, Ozakin C Rev Assoc Med Bras (1992). 2023; 69(11):e20230727.

PMID: 37820167 PMC: 10561911. DOI: 10.1590/1806-9282.20230727.

Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan.

Chen T, Chang Y, Wu Y Pathogens. 2023; 12(6).

PMID: 37375531 PMC: 10301606. DOI: 10.3390/pathogens12060841.

The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy.

Anastasia A, Bonura S, Rubino R, Giammanco G, Micciche I, Di Pace M Antibiotics (Basel). 2023; 12(6).

PMID: 37370290 PMC: 10295113. DOI: 10.3390/antibiotics12060971.

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.

Kowalska-Krochmal B, Maczynska B, Ruranska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M Pathogens. 2022; 11(12).

PMID: 36558775 PMC: 9786176. DOI: 10.3390/pathogens11121441.

Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand.

Thampithak A, Chaisiri K, Siangsuebchart O, Phengjaturat K, Aonjumras W, Hemapanpairoa J Infect Chemother. 2022; 54(4):699-710.

PMID: 36450288 PMC: 9840959. DOI: 10.3947/ic.2022.0098.

References

Zhanel G, Walkty A, Karlowsky J . Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can J Infect Dis Med Microbiol. 2016; 2016:2082693. PMC: 4904571. DOI: 10.1155/2016/2082693. View

Docobo-Perez F, Drusano G, Johnson A, Goodwin J, Whalley S, Ramos-Martin V . Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015; 59(9):5602-10. PMC: 4538498. DOI: 10.1128/AAC.00752-15. View

Falagas M, Vouloumanou E, Samonis G, Vardakas K . Fosfomycin. Clin Microbiol Rev. 2016; 29(2):321-47. PMC: 4786888. DOI: 10.1128/CMR.00068-15. View

Apisarnthanarak A, Mundy L . Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis. 2010; 51(11):1352-4. DOI: 10.1086/657249. View

Drobnic L, Quiles M, Rodriguez A . A study of the levels of fosfomycin in the cerebrospinal fluid in adult meningitis. Chemotherapy. 1977; 23 Suppl 1:180-8. DOI: 10.1159/000222045. View

Miro J, Entenza J, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C . High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012; 56(8):4511-5. PMC: 3421550. DOI: 10.1128/AAC.06449-11. View

Sumano L, Ocampo C, Gutierrez O . Intravenous and intramuscular pharmacokinetics of a single-daily dose of disodium-fosfomycin in cattle, administered for 3 days. J Vet Pharmacol Ther. 2007; 30(1):49-54. DOI: 10.1111/j.1365-2885.2007.00812.x. View

Kaye K, Rice L, Dane A, Stus V, Sagan O, Fedosiuk E . Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019; 69(12):2045-2056. PMC: 6880332. DOI: 10.1093/cid/ciz181. View

Schintler M, Traunmuller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O . High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009; 64(3):574-8. DOI: 10.1093/jac/dkp230. View

10.

Florent A, Chichmanian R, Cua E, Pulcini C . Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2010; 37(1):82-3. DOI: 10.1016/j.ijantimicag.2010.09.002. View

11.

Saiprasad P, Krishnaprasad K . Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections. Indian J Med Microbiol. 2016; 34(4):416-420. DOI: 10.4103/0255-0857.195379. View

12.

Gennari F . Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin. 2002; 18(2):273-88, vi. DOI: 10.1016/s0749-0704(01)00009-4. View

13.

Hashemian S, Farhadi Z, Farhadi T . Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag. 2019; 15:525-530. PMC: 6441553. DOI: 10.2147/TCRM.S199119. View

14.

Bandeira M, Carvalho P, Duarte A, Jordao L . Exploring Dangerous Connections between Klebsiella pneumoniae Biofilms and Healthcare-Associated Infections. Pathogens. 2014; 3(3):720-31. PMC: 4243437. DOI: 10.3390/pathogens3030720. View

15.

Maraki S, Samonis G, Rafailidis P, Vouloumanou E, Mavromanolakis E, Falagas M . Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009; 53(10):4508-10. PMC: 2764175. DOI: 10.1128/AAC.00721-09. View

16.

Karageorgopoulos D, Wang R, Yu X, Falagas M . Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2011; 67(2):255-68. DOI: 10.1093/jac/dkr466. View

17.

Rosso-Fernandez C, Sojo-Dorado J, Barriga A, Lavin-Alconero L, Palacios Z, Lopez-Hernandez I . Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015; 5(3):e007363. PMC: 4386243. DOI: 10.1136/bmjopen-2014-007363. View

18.

Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas M . Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2009; 16(2):184-6. DOI: 10.1111/j.1469-0691.2009.02921.x. View

19.

Falagas M, Kastoris A, Kapaskelis A, Karageorgopoulos D . Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010; 10(1):43-50. DOI: 10.1016/S1473-3099(09)70325-1. View

20.

Silver L . Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med. 2017; 7(2). PMC: 5287057. DOI: 10.1101/cshperspect.a025262. View